Cefazolin plus ertapenem and heart transplantation as salvage therapy for refractory LVAD infection due to methicillin-susceptible Staphylococcus aureus: A case series.
Jorge L Cardenas-AlvarezJose SuarezGabriel MotoaShweta AnjanYoichiro NatoriMatthias LoebeJoao Roberto BredaNina Thakkar-RiveraAnita PhancaoAli GhodsizadJoseph E BauerleinMrudula R MunagalaJacques SimkinsPublished in: Journal of cardiac surgery (2021)
The use of left ventricular assist devices (LVADs) is increasingly more common as the availability of donor organs in relation to failing hearts is outstandingly limited. Infections are the most common complications in LVAD recipients, particularly those caused by Staphylococcus spp. Refractory LVAD-related infections are not uncommon as achieving adequate source control is often not feasible before heart transplantation. Evidence suggest that cefazolin plus ertapenem is effective in refractory methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, but this approach has not been described in LVAD recipients. In this article, we report two cases of refractory MSSA bacteremia in LVAD recipients that were successfully treated with salvage therapy with cefazolin plus ertapenem and subsequent heart transplantation. This treatment strategy should be considered in patients with refractory LVAD-associated infection due to MSSA that are not responding to standard treatment.
Keyphrases
- staphylococcus aureus
- left ventricular assist device
- biofilm formation
- left ventricular
- methicillin resistant staphylococcus aureus
- kidney transplantation
- heart failure
- pseudomonas aeruginosa
- coronary artery disease
- atrial fibrillation
- mitral valve
- gram negative
- mesenchymal stem cells
- aortic stenosis
- percutaneous coronary intervention
- drug induced
- left atrial
- transcatheter aortic valve replacement